Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Boehringer Ingelheim
Johnson and Johnson
Colorcon
Mallinckrodt

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Patent: 8,137,919

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,137,919
Title:Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
Abstract: A method of determining if a cancer patient is amenable to treatment with EGFR inhibitors including but not limited to cetuximab, panitumumab or erlotinib by the following steps: (a) Obtaining cells from a cancer patient\'s tumor; (b) Determining if said cells contain a biomarker that is predictive of a therapeutic response to response to treatment with cetuximab or panitumumab. The biomarker is the mutation status of the PIK3CA gene and the expression status of the PTEN gene. Tumors that harbor activating mutations in Exon 9 and 20 of the PIK3CA gene or which show loss of PTEN protein expression will be considered not likely to benefit from EGFR targeting therapies.
Inventor(s): Mariadason; John M. (Balwyn, AU), Goel; Sanjay (Syosset, NY)
Assignee: Montefiore Medical Center (Bronx, NY)
Application Number:12/384,826
Patent Claims:see list of patent claims

Details for Patent 8,137,919

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2004-02-12 ⤷  Free Forever Trial 2028-04-10
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2007-03-28 ⤷  Free Forever Trial 2028-04-10
Amgen, Inc. VECTIBIX panitumumab Injection 125147 2006-09-27 ⤷  Free Forever Trial 2028-04-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Colorcon
Baxter
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.